| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/MOL.54.6.962 |
| P698 | PubMed publication ID | 9855623 |
| P50 | author | Albert Smolenski | Q52355389 |
| P2093 | author name string | Koesling D | |
| Schultz G | |||
| Walter U | |||
| Friebe A | |||
| Müllershausen F | |||
| P433 | issue | 6 | |
| P921 | main subject | carbon monoxide | Q2025 |
| P304 | page(s) | 962-967 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. | |
| P478 | volume | 54 |
| Q35046026 | A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury |
| Q42049434 | A-350619: a novel activator of soluble guanylyl cyclase |
| Q41485148 | Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. |
| Q41903134 | Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats |
| Q42863913 | Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase |
| Q35044037 | Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies |
| Q39209626 | Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease |
| Q42599401 | Cyclic GMP protects human macrophages against peroxynitrite-induced apoptosis |
| Q35138860 | Cyclic nucleotide signalling in kidney fibrosis |
| Q41765778 | Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach |
| Q36324241 | Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling |
| Q44407152 | Effect of Carbon Monoxide on Dopamine and Glutamate Uptake and cGMP Levels in Rat Brain |
| Q93551725 | Enzymes |
| Q35765882 | Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition |
| Q28345164 | Functional coupling between nitric oxide synthesis and VIP release within enteric nerve terminals of the rat: involvement of protein kinase G and phosphodiesterase 5 |
| Q80502244 | Guanylate cyclase activators influence reactivity of human mesenteric superior arteries retrieved and preserved in the same conditions as transplanted kidneys |
| Q39968459 | In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation |
| Q43972677 | Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. |
| Q43733608 | Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils |
| Q41861146 | Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors |
| Q43981271 | Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms |
| Q43564835 | Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. |
| Q46261374 | Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat. |
| Q34599889 | Isoforms of NO-sensitive guanylyl cyclase |
| Q37327376 | Lack of effect of ODQ does not exclude cGMP signalling via NO-sensitive guanylyl cyclase. |
| Q37352802 | Modulating cGMP to treat lung diseases. |
| Q36713981 | Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking |
| Q24656131 | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential |
| Q37655398 | New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications |
| Q35044042 | Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies |
| Q58603529 | Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery |
| Q43032725 | Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells |
| Q44485505 | Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway |
| Q43782834 | Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism |
| Q35045463 | Properties of NO-activated guanylyl cyclases expressed in cells |
| Q35084643 | Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses |
| Q42951390 | Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme |
| Q33179221 | Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase |
| Q45959130 | Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus. |
| Q35010064 | Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
| Q35075847 | Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
| Q93498508 | Soluble guanylyl cyclase (E.C. 4.6.1.2) |
| Q58075704 | Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation |
| Q42355197 | Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality |
| Q30486745 | The Concise Guide to PHARMACOLOGY 2013/14: enzymes. |
| Q35044932 | The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum |
| Q34973860 | The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects |
| Q44587864 | The enhanced NO-induced cGMP response induced by long-term L-NAME treatment is not due to enhanced expression of NO-sensitive guanylyl cyclase |
| Q35236498 | The neuronal nitric oxide synthase (nNOS) gene and neuroprotection against alcohol toxicity |
| Q37209592 | The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms |
| Q30503997 | Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration |
| Q42222825 | Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule |
| Q83227469 | Wedging open a catalytic site |
| Q33948966 | YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components |
| Q35044436 | YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells |
| Q35041586 | YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea. |
| Q39672848 | YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. |
| Q43791947 | cGMP signalling beyond nitric oxide |
| Q34244951 | cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action |
| Q112995493 | sGC stimulators bind sGC:NO |
Search more.